Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.65 |
| ▸ | ACE | P12821 | 4/20 | 0.65 |
| ▸ | MMEL1 | Q495T6 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17746035 | 1.00 | MME (0.65) | MMEACEMMEL1 | |
| SCHEMBL25129465 | 0.95 | MME (0.64) | MMEACEMMEL1 | |
| SCHEMBL21727312 | 0.95 | MME (0.64) | MMEACEMMEL1 | |
| SCHEMBL28456484 | 0.94 | MME (0.76) | MMEACEMMEL1 | |
| SCHEMBL7436015 | 0.94 | MME (0.76) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL22420467 | 0.92 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL8214132 | 0.92 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL1908525 | 0.92 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059568 | 0.92 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL2707112 | 0.92 | MME (0.77) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | claimed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | claimed |
| CN-109803657-B | Pharmaceutical composition | 武汉朗来科技发展有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110237072-B | Process for preparing pharmaceutical composition | 武汉朗来科技发展有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-110237071-B | Pharmaceutical preparation and use thereof | 武汉朗来科技发展有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | disclosed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | MME, ANPEP, TMPRSS15 | MME 1/4885ACE 32/4885MMEL1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.